Scholarlink

<p>Timely diagnosis is critical for improving breast cancer outcomes, especially in resource-limited health systems. This study provides the first real-world evidence from Bosnia and Herzegovina on diagnostic and treatment intervals, adherence, and survival in women with breast cancer. We conducted a retrospective analysis of breast cancer cases diagnosed between 2019 and 2023 at the Clinical Centre University of Sarajevo, the largest cancer center in the country, managing approximately 60% of cases in the Federation of Bosnia and Herzegovina. Most patients (78.1%; 95% CI: 73.8–82.3) were diagnosed through self-referral due to symptoms, with 62.4% of cancers detected at stages 1 and 2. The mean patient and system diagnostic intervals were 38.1 days (95% CI: 23.4–52.8) and 38.6 days (95% CI: 29.9–47.3), respectively, with a total diagnostic interval of 70 days (95% CI: 58.9–82.5). Almost all diagnostic procedures had a waiting time of less than ten days. Among all women undergoing surgery, radical mastectomy was performed in 61% (95% CI: 55–66), while among women with stage 1–2 disease, 55% (95% CI: 48–62) underwent radical mastectomy. Treatment duration averaged 3.7 months for chemotherapy (95% CI: 3.4–4.1) and 0.48 months for radiotherapy (95% CI: 0.26–0.69), with higher compliance for radiotherapy (99.5%; 95% CI: 98–100) than chemotherapy (78%; 95% CI: 72–84). Three-year progression-free survival was 85.7%, and overall three-year survival was 86%. Early breast cancer detection and favorable survival can be achieved even in resource-constrained settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Breast cancer in Bosnia and Herzegovina: real-world patterns of diagnosis, treatment, and survival outcomes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月3日

查看全文
  • Semir Bešlija,
  • Emir Sokolović,
  • Timur Cerić,
  • Anes Pašić,
  • Azra Grebo,
  • Amina Aljić,
  • Layan Mattar,
  • Courtney Freedman,
  • Olena Doroshenko,
  • Olena Mandrik

摘要

Timely diagnosis is critical for improving breast cancer outcomes, especially in resource-limited health systems. This study provides the first real-world evidence from Bosnia and Herzegovina on diagnostic and treatment intervals, adherence, and survival in women with breast cancer. We conducted a retrospective analysis of breast cancer cases diagnosed between 2019 and 2023 at the Clinical Centre University of Sarajevo, the largest cancer center in the country, managing approximately 60% of cases in the Federation of Bosnia and Herzegovina. Most patients (78.1%; 95% CI: 73.8–82.3) were diagnosed through self-referral due to symptoms, with 62.4% of cancers detected at stages 1 and 2. The mean patient and system diagnostic intervals were 38.1 days (95% CI: 23.4–52.8) and 38.6 days (95% CI: 29.9–47.3), respectively, with a total diagnostic interval of 70 days (95% CI: 58.9–82.5). Almost all diagnostic procedures had a waiting time of less than ten days. Among all women undergoing surgery, radical mastectomy was performed in 61% (95% CI: 55–66), while among women with stage 1–2 disease, 55% (95% CI: 48–62) underwent radical mastectomy. Treatment duration averaged 3.7 months for chemotherapy (95% CI: 3.4–4.1) and 0.48 months for radiotherapy (95% CI: 0.26–0.69), with higher compliance for radiotherapy (99.5%; 95% CI: 98–100) than chemotherapy (78%; 95% CI: 72–84). Three-year progression-free survival was 85.7%, and overall three-year survival was 86%. Early breast cancer detection and favorable survival can be achieved even in resource-constrained settings.